GlaxoSmithKline and Amgen are parting ways on Prolia, their comarketed osteoporosis med that's been among the fastest-growing products approved in the last few years. Amgen will take over the task in most areas under their agreement, leaving GSK freer to buckle down on some new launches of its own.
The biotech IPO window is open, and Radius Health is preparing to see if it can make the leap and land on Wall Street with about $86 million in hand.
A newly discovered mechanism that promotes bone growth could lead to novel treatments for osteoporosis, which affects an estimated one in three women and one in 12 men in the U.S..
Researchers in Finland have come up with a new application for well-known materials known as bisphosphonates that includes a possible role for drug delivery.
Researchers have developed self-powered nanoparticles to carry drugs into tiny cracks in bones, a process that could help treat osteoporosis in its early stages. And the fuel for the nanovehicles' bone-delving ability comes from the bone itself.
Just a few months after Amgen execs lamented a big Asian gap in their global strategy, the Big Biotech company has joined hands with Astellas to set up a new joint venture in Japan. Amgen is contributing 5 experimental-stage programs to the JV, including their late-stage anti-PCSK9 program for the cholesterol drug AMG-145.
It's Fosamax trial time again. Amid litigation over the bone drug's risks of jawbone injury, Merck is in court to fight claims that Fosamax caused patients' femur fractures. Once again, the drugmaker faces charges that it ignored the drug's safety risks, leaving patients in the dark.
New restrictions may be in store for a long-used set of bone-building drugs. Worried about a possible increase in cancer risk--and unconvinced of the drugs' benefits--an FDA advisory panel voted against using calcitonin salmon products in osteoporosis patients.
Merck is in a world of hurt. The pharma giant managed to spook several analysts with the news that its osteoporosis drug odanacatib would be held back from regulators until more data could be obtained in a trial extension, raising fears that the badly needed drug may be about to jump the tracks.
Osseon Therapeutics pulled in $14 million in new equity financing to help fuel development and expansion of its devices designed to treat vertebral compression fractures.